β-blockers in chronic heart failure: Considerations for selecting an agent

Mayo Clinic Proceedings

Volumn 77, Issue 11, 2002, Pages 1199-1206

  Kukin, Marrick L ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BUCINDOLOL; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; METOPROLOL; METOPROLOL TARTRATE; NEBIVOLOL; PLACEBO; PROPRANOLOL; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ADRENERGIC SYSTEM; ANIMAL MODEL; APOPTOSIS; ASTHMA; BRADYCARDIA; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CHRONIC DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG MECHANISM; DRUG PREFERENCE; DRUG SELECTIVITY; FLUID RETENTION; HEART BLOCK; HEART FAILURE; HUMAN; HYPOTENSION; LIPID PEROXIDATION; MAJOR CLINICAL STUDY; META ANALYSIS; MORTALITY; MULTICENTER STUDY; NONHUMAN; OXIDATIVE STRESS; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SURVIVAL RATE; SUSTAINED RELEASE FORMULATION; TREATMENT OUTCOME; VASODILATATION; VERTIGO; VISUAL IMPAIRMENT; WEIGHT GAIN;

EID: 0036842306     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/77.11.1199     Document Type: Review

References (58)

1. Packer M, Cohn JN, Advisory Council to Improve Outcomes Nationwide in Heart Failure. Consensus recommendations for the management of chronic heart failure. Am J Cardiol. 1999;83(2A):1A-38A.
2. Sabbah HN. The cellular and physiologic effects of beta blockers in heart failure. Clin Cardiol. 1999;22(suppl 5):V16-V20.
3. Colucci WS. The effects of norepinephrine on myocardial biology: Implications for the therapy of heart failure. Clin Cardiol. 1998;21(12, suppl 1):I20-I24.
4. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomised trial. Lancet. 1999;353:9-13.
5. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:2001-2007.
6. Packer M, Bristow MR, Cohn JN, et al, U.S. Carvedilol Heart Failure Study Group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 1996;334:1349-1355.
7. Packer M, Coats AJ, Fowler MB, et al, Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344:1651-1658.
8. Heart Failure Society of America. HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction - Pharmacological approaches. Pharmacotherapy. 2000;20:495-522.
9. Australia/New Zealand Heart Failure Research Collaborative Group. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet. 1997;349:375-380.
10. CIBIS Investigators and Committees. A randomized trial of β-blockade in heart failure: The Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation. 1994;90:1765-1773.
11. Waagstein F, Bristow MR, Swedberg K, et al, Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet. 1993;342:1441-1446.
12. Carson PE. Beta blocker treatment in heart failure. Prog Cardiovasc Dis. 1999;41:301-321.
13. Heidenreich PA, Lee TT, Massie BM. Effect of beta-blockade on mortality in patients with heart failure: A meta-analysis of randomized clinical trials. J Am Coll Cardiol. 1997;30:27-34.
14. Lechat P, Packer M, Chalon S, Cucherat M, Arab T, Boissel JP. Clinical effects of β-adrenergic blockade in chronic heart failure: A meta-analysis of double-blind, placebo-controlled, randomized trials. Circulation. 1998;98:1184-1191.
15. Hjalmarson Å, Goldstein S, Fagerberg B, et al, MERIT-HF Study Group. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: The Metoprolol CR/XL Randomized Intervention Trial in congestive Heart Failure (MERIT-HF). JAMA. 2000;283:1295-1302.
16. Beta-Blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med. 2001;344:1659-1667.
17. McMurray JJV. Major β blocker mortality trials in chronic heart failure: A critical review. Heart. 1999;82(suppl 4):IV14-IV22.
18. Pfeffer MA, Stevenson LW. Beta-adrenergic blockers and survival in heart failure [editorial]. N Engl J Med. 1996;334:1396-1397.
19. Goldstein S, Fagerberg B, Hjalmarson Å, et al, MERIT-HF Study Group. Metoprolol controlled release/extended release in patients with severe heart failure: Analysis of the experience in the MERIT-HF study. J Am Coll Cardiol. 2001;38:932-938.
20. Bristow MR. β-adrenergic receptor blockade in chronic heart failure. Circulation. 2000;101:558-569.
21. Kukin ML IV. Are all β blockers the same for heart failure? Congest Heart Fail. 2000;6:153-157.
22. Bristow MR, Larrabee P, Minobe W, et al. Receptor pharmacology of carvedilol in the human heart. J Cardiovasc Pharmacol. 1992;19(suppl 1):S68-S80.
23. Bristow MR, Roden RL, Lowes BD, Gilbert EM, Eichhorn EJ. The role of third-generation beta-blocking agents in chronic heart failure [published correction appears in Clin Cardiol. 1999;22:March]. Clin Cardiol. 1998;21(12, suppl 1)I3-I13.
24. Gilbert EM, Anderson JL, Deitchman D, et al. Long-term β-blocker vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy: A double-blind, randomized study of bucindolol versus placebo. Am J Med. 1990;88:223-229.
25. Gilbert EM, Abraham WT, Olsen S, et al. Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation. 1996;94:2817-2825.
26. Lowes BD, Chidiac P, Olsen S, et al. Clinical relevance of inverse agonism and guanine nucleotide modulatable binding properties of β adrenergic receptor blocking agents [abstract]. Circulation. 1994;90(4, pt 2):I-543. Abstract 2925.
27. Andreka P, Aiyar N, Olson LC, et al. Bucindolol displays intrinsic sympathomimetic activity in human myocardium. Circulation. 2002;105:2429-2434.
28. Yoshikawa T, Port JD, Asano K, et al. Cardiac adrenergic receptor effects of carvedilol. Eur Heart J. 1996;17(suppl B):8-16.
29. Bristow MR. What type of β-blocker should be used to treat heart failure? [editorial]. Circulation. 2000;102:484-486.
30. Soriano JB, Hoes AW, Meems L, Grobbee DE. Increased survival with β-blockers: Importance of ancillary properties. Prog Cardiovasc Dis. 1997;39:445-456.
31. Cohn JN. Structural basis for heart failure: Ventricular remodeling and its pharmacologic inhibition [editorial]. Circulation. 1995;91:2504-2507.
32. Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction: Experimental observations and clinical implications. Circulation. 1990;81:1161-1172.
33. Kukin ML, Kalman J, Charney RH, et al. Prospective, randomized comparison of effect of long-term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction, and oxidative stress in heart failure. Circulation. 1999;99:2645-2651.
34. Sanderson JE, Chan SK, Yip G, et al. Beta-blockade in heart failure: A comparison of carvedilol with metoprolol. J Am Coll Cardiol. 1999;34:1522-1528.
35. Metra M, Giubbini R, Nodari S, Boldi E, Modena MG, Dei Cas L. Differential effects of β-blockers in patients with heart failure: A prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol. Circulation. 2000;102:546-551.
36. Eichhom EJ, Bristow MR. Practical guidelines for initiation of beta-adrenergic blockade in patients with chronic heart failure [editorial]. Am J Cardiol. 1997;79:794-798.
37. Belch JJ, Bridges AB, Scott N, Chopra M. Oxygen free radicals and congestive heart failure. Br Heart J. 1991;65:245-248.
38. Ruffolo RR Jr, Feuerstein GZ. Neurohormonal activation, oxygen free radicals, and apoptosis in the pathogenesis of congestive heart failure. J Cardiovasc Pharmacol. 1998;32(suppl 1):S22-S30.
39. Rossig L, Haendeler J, Mallat Z, et al. Congestive heart failure induces endothelial cell apoptosis: Protective role of carvedilol. J Am Coll Cardiol. 2000;36:2081-2089.
40. Yue TL, Mckenna PJ, Gu JL, Cheng HY, Ruffolo RR Jr, Feuerstein GZ. Carvedilol, a new antihypertensive agent, prevents lipid peroxidation and oxidative injury to endothelial cells. Hypertension. 1993;22:922-928.
41. Arumanayagam M, Chan S, Tong S, Sanderson JE. Antioxidant properties of carvedilol and metoprolol in heart failure: A doubleblind randomized controlled trial. J Cardiovasc Pharmacol. 2001;37:48-54.
42. Lysko PG, Webb CL, Gu JL, Ohlstein EH, Ruffolo RR Jr, Yue TL. A comparison of carvedilol and metoprolol antioxidant activities in vitro. J Cardiovasc Pharmacol. 2000;36:277-281.
43. Sharov VG, Sabbah HN, Shimoyama H, Goussev AV, Lesch M, Goldstein S. Evidence of cardiocyte apoptosis in myocardium of dogs with chronic heart failure. Am J Pathol. 1996;148:141-149.
44. Krown KA, Page MT, Nguyen C, et al. Tumor necrosis factor alpha-induced apoptosis in cardiac myocytes: Involvement of the sphingolipid signaling cascade in cardiac cell death. J Clin Invest. 1996;98:2854-2865.
45. Cheng W, Li B, Kajstura J, et al. Stretch-induced programmed myocyte cell death. J Clin Invest. 1995;96:2247-2259.
46. 2-adrenergic receptors on cardiac myocyte apoptosis: Role of a pertussis toxin-sensitive G protein. Circulation. 1999;100:2210-2212.
47. Feuerstein G, Liu GL, Yue TL, et al. Comparison of metoprolol and carvedilol pharmacology and cardioprotection in rabbit ischemia and reperfusion model. Eur J Pharmacol. 1998;351:341-350.
48. Hjalmarson Å, Kneider M, Waagstein F. The role of β-blockers in left ventricular dysfunction and heart failure. Drugs. 1997;54:501-510.
49. Doughty RN. Beta-blockers for advanced heart failure - How far can you go? Eur J Heart Fail. 1999;1:259-262.
50. Anthonio RL, van Veldhuisen DJ, Breekland A, Crijns HJ, van Gilst WH. Beta-blocker titration failure is independent of severity of heart failure. Am J Cardiol. 2000;85:509-512.
51. Coreg [Package Insert]. Philadelphia, Pa: SmithKline Beecham Pharmaceuticals; 1999.
52. Toprol-XL [Package Insert]. Wilmington, Del: AstraZeneca: 2001.
53. Kukin ML, Mannino MM, Freudenberger RS, Kalman J, Buchholz-Varley C, Ocampo O. Hemodynamic comparison of twice daily metoprolol tartrate with once daily metoprolol succinate in congestive heart failure. J Am Coll Cardiol. 2000;35:45-50.
54. Bristow MR, O'Connell JB, Gilbert EM, et al, Bucindolol Investigators. Dose-response of chronic β-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Circulation. 1994;89:1632-1642.
55. Bristow MR, Gilbert EM, Abraham WT, et al, MOCHA Investigators. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation. 1996;94:2807-2816.
56. Morimoto SI, Shimizu K, Yamada K, Hiramitsu S, Hishida H. Can beta-blocker therapy be withdrawn from patients with dilated cardiomyopathy? Am Heart J. 1999;138(3 pt 1):456-459.
57. Waagstein F, Caidahl K, Wallentin I, Bergh CH, Hjalmarson Å. Long-term β-blockade in dilated cardiomyopathy: Effects of short- and long-term metoprolol treatment followed by withdrawal and readministration of metoprolol. Circulation. 1989;80:551-563.
58. Agewall S, Kendall M. Treatment with beta-blockers - The value of an even plasma concentration over 24 h [published correction appears in J Clin Pharm Ther. 1997;22:303]. J Clin Pharm Ther. 1997;22:171-179.